The global pork tapeworm infection treatment market is expected to reach US$ 11.66 Billion in 2023 and is projected to exhibit a CAGR of 8% from 2023 to 2033. As tapeworms become more prevalent, oral medications to treat them are becoming more popular. Despite its prevalence in poor rural countries around the world, Taenia solium continues to pose a serious public health threat. The parasite Neurocysticercosis (NCC) causes severe neurological infections in endemic regions, causing up to one-third of seizure disorders.
In partnership with Bayer AG, the World Health Organization renewed its collaboration which expanded assistance to millions of people suffering from neglected tropical diseases (NTD). There were also medicines from Bayer donated to support the control of cysticercosis and taeniasis.
Tapeworm infestations are being researched, but no new treatments have been approved for pork tapeworms. Plant-based compounds are being explored as a technique for preventing tapeworms from absorbing nutrients, and viruses engineered with genetic material are being investigated for killing tapeworm eggs. In addition, probiotics are being explored as a way to combat parasites. In the future, new treatments are expected to become available, but pork tapeworm medications are not yet approved.
It is imperative that the world's leading producers of pork tapeworm infection treatment expand their production facilities and retaining competitiveness in the pork tapeworm infection treatment market requires establishing long-term distribution agreements with large local distribution firms. A number of tests are being undertaken by companies in order to ensure the accuracy of the results in the market.
| Data Points | Key Statistics |
|---|---|
| Estimated Base Year Value (2022) | US$ 11 Billion |
| Expected Market Value (2023) | US$ 11.66 Billion |
| Anticipated Forecast Value (2033) | US$ 25.17 Billion |
| Projected Growth Rate (2023 to 2033) | 8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to a report from Future Market Insights (FMI), from 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.2%. As health awareness rises, and there is a high incidence of foodborne diseases such as tapeworm infection, the pork tapeworm infection treatment market is expected to grow rapidly.
Approximately 50 million people suffer from epilepsy worldwide, and more than 80 percent live in developing countries. The most effective way to control and break the life cycle of the parasite requires detailed case findings, better diagnosis and treatment, and public health information campaigns. With the aim of reducing the burden of PPBDs among ethnic minority communities in Vietnam, the Safer Indigenous Pork and Healthy Minorities project from January 2018 to June 2020 was developed.
Researchers studying the treatment of pork tapeworm infections have the potential to develop new treatments, treatment strategies, and diagnostic tools that can support the fight against this infection. A new diagnostic technique or drug, a vaccine, or some preventative measure might be among them. There may also be new avenues for treatment to be explored as researchers continue to investigate the biology and genetic makeup of the parasite. Further studies undertaken into the epidemiology of this disease may also help provide insights into the way in which it can be controlled and prevent its spread in the future.
There is a strong likelihood that the increased awareness about sanitizing hands and being able to cook food thoroughly in the future will further drive the market demand for pork tapeworm infection treatment. The global demand for pork tapeworm infection treatment is projected to increase at a CAGR of 11% during the forecast period between 2023 and 2033, reaching a total of US$ 25.17 Billion in 2033.
Governmental Awareness Programs will enhance the Growth of the Market
Foods derived from animals are becoming increasingly concerned about food safety, especially those that are required to meet people's nutritional needs, especially women and children. Due to low awareness of infection risks and higher unhygienic places in urban and rural areas, the market is predicted to grow. Over the forecast period, the market is expected to grow due to the increasing incidence of tapeworms, as well as high investment in tapeworm treatment research. Several government-sponsored awareness campaigns regarding cattle and pork infections have pushed market demand for the treatments due to increased research and development funding.
As part of this program, efforts are being coordinated between the Ministry of Women and Child Development, the Department of School Education and Literacy of the Ministry of Human Resources and Development, and the Ministry of Drinking Water and Sanitation. As part of deworming program support, the Ministry of Panchayati Raj, Ministry of Tribal Affairs, Ministry of Rural Development, Ministry of Urban Development, and Urban Local Bodies (ULBs) have also stepped forward.
New Vaccines and Drugs will drive Market Growth in the Future
Researchers are developing new vaccines and medications to treat pork tapeworms. With the invention of drug therapies that target the parasite's life cycle, as well as vaccines to prevent the infection from occurring at all, new drugs can be made available to help reduce the global burden of disease caused by pork tapeworms. Pork tapeworms cause a large number of diseases globally. These tools could make a big difference. It is anticipated that one or more pharmaceutical companies will invest in the development of new drugs intended to target pork tapeworms specifically.
In addition to developing an anthelmintic strategy targeting the tapeworm adult, research is underway to develop anthelmintic cocktails targeting the tapeworm at multiple stages of its life cycle. Further studies are also underway to develop vaccines that could potentially reduce the risk of pork tapeworm infection through the development of vaccines. It is most common to contract the parasite at the larval stage, so these vaccines are targeting this stage of infection. Infection with pork tapeworms can be treated better and more effectively with the help of all these efforts.
Principal Consultant
Lack of awareness and Timely Treatment will limit the expansion
Approximately half of all pig tapeworm infections are not diagnosed and are not treated because of the delay in diagnosing them, hence the market is expected to hamper. In addition, limited drug development combined with a high cost for the diagnosis is expected to make the growth of the market difficult.
Nevertheless, higher research and development costs as well as high adverse reaction rates caused due to the inflammatory reaction of the body are key factors limiting global pork tapeworm infection treatment demand.
Governmental Guidelines to Surge the Market Demand for Drugs and Treatments
North America is estimated to account for the second-largest segment of the global pork tapeworm infection treatment market during the forecast period. A government guideline was published regarding the treatment of these infections, as well as the use of albendazole.
For instance, AAN (American Academy of Neurology) released a set of evidence-based guidelines that are intended to treat neurocysticercosis, a tapeworm infection that causes seizures, and is on the rise in developed countries. Neurocysticercosis is also considered a health threat in the United States. American Academy of Neurology's medical journal Neurology published the guideline on April 9, 2013. A combination of albendazole and a corticosteroid was found to be effective in treating neurocysticercosis following a review of all available evidence. In order to get rid of the parasite, albendazole was taken as a medication.
As Economic Conditions Change and Cattle Restocking Increases, Pork Tapeworm Infections are on the Rise
According to forecasts, Europe will hold the largest market for pork tapeworm infection treatment. In this region, pork tapeworm infection treatments account for 28% of the total market. Europe's success has been largely attributed to its high diagnosis rates, modern medical facilities, and increased research and development efforts. Taenia solium exists as an endemic species throughout the world. As a result of industrialization and improved sanitation, this parasite is believed to have been eradicated from Europe's pig-rearing systems.
Increasing cattle rearing practices and raw meat consumption have prone consumers to tapeworm infections, so the market for advanced treatments is expected to grow. It is anticipated that a greater awareness program about infections and education in this area will also contribute to the growth of the market in the future. As economic conditions improve and spending habits increase, the pork tapeworm infection treatment market is expected to grow.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Increased Awareness About Veterinary Care is Driving Market Growth
The market for the albendazole drug type is expected to grow at a CAGR of 6.2% from 2023 to 2033. As albendazole is FDA-approved for treating various parasitic worm infections, the market for these drugs is expected to grow. Increasing demand for these drugs is expected to fuel growth in the market for treating various infections in humans and animals.
Roundworms, tapeworms, hookworms, and other helminths are projected to increase in prevalence, causing an increase in the demand for antihelmintic drugs in the market. The number of albendazole drugs sold in developing countries is substantial since these regions are often the victims of tapeworm infections, which often cause them to buy albendazole drugs. There is also a possibility that the modernization of the healthcare industry will increase the number of opportunities on the market in the near future. Further, researchers are developing novel formulations of albendazole with the aim of optimizing the drug's therapeutic effectiveness by transferring the drug into micro-emulsifying delivery systems and increasing the lipid-solubility of the dosage form.
Demand for Advanced Diagnostic Tools to Treat Pork Tapeworm Infection will Increase
Based on the treatment, the global market is segmented into CT scans, MRI, Ultrasound, and X-rays. Revenues from CT scans are forecast to grow by 22% during the forecast period. X-rays, CT scans, MRI scans, or ultrasounds can be used to detect invasive tapeworm infections. Advances in technology and advanced machines to detect illness are driving the growth of these tools in the market.
Most people with cysticercosis do not have positive stool tests for pork tapeworms, according to the Merck Manual. In the case of individuals that exhibit symptoms of an infection in their nervous system, two imaging tests are often used to diagnose cysticercosis or neurocysticercosis: computed tomography (CT) scans and magnetic resonance imaging (MRI). Due to the increased availability and affordability of these tests, especially in developing regions, the market for these tests for pork tapeworm infection treatment is expected to grow.
Some of the start-ups in the pork tapeworm infection treatment market include-
By increasing production and meeting consumer demands, strategic partnerships can help manufacturers boost revenue and market share. Promote new products and technologies to end users so they can benefit from their use. A partnership can increase a company's production capacity by forming a strategic partnership.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 11.66 Billion |
| Market Value in 2033 | US$ 25.17 Billion |
| Growth Rate | CAGR 8% |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
Drug Type, Treatment, End User, Distribution Channel, Region |
| Regions Covered |
North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | Winchester Hospital; Merck & Company Inc.; Medtronic; Teva Pharmaceuticals Ltd.; Eli Lilly and Company; Sanofi S.A.; Bayer AG; Bristol-Myers Squibb; Abbott; Recordati Rare Diseases Inc. |
| Customization | Available Upon Request |
The market is valued at US$ 11.66 Billion in 2023.
Winchester Hospital, Merck & Company Inc. and Medtronic are key market players.
Albendazole drug market to grow 6.2% CAGR (2023-2033).
From 2018 to 2022, the market registered a 5.2% CAGR.
Europe will hold a 28% share in 2023.
1. Executive Summary | Pork Tapeworm Infection Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ million) Analysis By Drug Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Type, 2023 to 2033
5.3.1. Praziquantel
5.3.2. Albendazole
5.3.3. Nitazoxanide
5.3.4. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ million) Analysis By Treatment, 2018 to 2022
6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Treatment, 2023 to 2033
6.3.1. CT scan
6.3.2. MRI
6.3.3. Ultrasound
6.3.4. X-ray
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ million) Analysis By End-Users, 2018 to 2022
7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By End-Users, 2023 to 2033
7.3.1. Hospitals & Laboratories
7.3.2. Specialty Clinics
7.3.3. Ambulatory Surgical Centres
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End-Users, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End-Users, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East and Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. The USA
10.2.1.2. Canada
10.2.2. By Drug Type
10.2.3. By Treatment
10.2.4. By End-Users
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Treatment
10.3.4. By End-Users
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Type
11.2.3. By Treatment
11.2.4. By End-Users
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. By Treatment
11.3.4. By End-Users
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. The United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Type
12.2.3. By Treatment
12.2.4. By End-Users
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Treatment
12.3.4. By End-Users
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Drug Type
13.2.3. By Treatment
13.2.4. By End-Users
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Treatment
13.3.4. By End-Users
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Type
14.2.3. By Treatment
14.2.4. By End-Users
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Type
14.3.3. By Treatment
14.3.4. By End-Users
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Drug Type
15.2.3. By Treatment
15.2.4. By End-Users
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Type
15.3.3. By Treatment
15.3.4. By End-Users
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Type
16.2.3. By Treatment
16.2.4. By End-Users
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Type
16.3.3. By Treatment
16.3.4. By End-Users
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. The USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Drug Type
17.1.2.2. By Treatment
17.1.2.3. By End-Users
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Drug Type
17.2.2.2. By Treatment
17.2.2.3. By End-Users
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Drug Type
17.3.2.2. By Treatment
17.3.2.3. By End-Users
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Drug Type
17.4.2.2. By Treatment
17.4.2.3. By End-Users
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Drug Type
17.5.2.2. By Treatment
17.5.2.3. By End-Users
17.5.2.4. By Distribution Channel
17.6. The United Kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Drug Type
17.6.2.2. By Treatment
17.6.2.3. By End-Users
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Drug Type
17.7.2.2. By Treatment
17.7.2.3. By End-Users
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Drug Type
17.8.2.2. By Treatment
17.8.2.3. By End-Users
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Drug Type
17.9.2.2. By Treatment
17.9.2.3. By End-Users
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Drug Type
17.10.2.2. By Treatment
17.10.2.3. By End-Users
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Drug Type
17.11.2.2. By Treatment
17.11.2.3. By End-Users
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Drug Type
17.12.2.2. By Treatment
17.12.2.3. By End-Users
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Drug Type
17.13.2.2. By Treatment
17.13.2.3. By End-Users
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Drug Type
17.14.2.2. By Treatment
17.14.2.3. By End-Users
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Drug Type
17.15.2.2. By Treatment
17.15.2.3. By End-Users
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Drug Type
17.16.2.2. By Treatment
17.16.2.3. By End-Users
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Drug Type
17.17.2.2. By Treatment
17.17.2.3. By End-Users
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Drug Type
17.18.2.2. By Treatment
17.18.2.3. By End-Users
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Drug Type
17.19.2.2. By Treatment
17.19.2.3. By End-Users
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Drug Type
17.20.2.2. By Treatment
17.20.2.3. By End-Users
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Drug Type
17.21.2.2. By Treatment
17.21.2.3. By End-Users
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Type
18.3.3. By Treatment
18.3.4. By End-Users
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Winchester Hospital
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Merck & Company Inc.
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Medtronic
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Teva Pharmaceuticals Ltd.
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Eli Lilly and Company
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Sanofi S.A.
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Bayer AG
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Bristol-Myers Squibb.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Abbott
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Recordati Rare Diseases Inc.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Pork Tapeworm Infection Treatment Market
